Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr Yang on the Results of the KEYNOTE-789 Trial in EGFR-mutant NSCLC

June 29th 2023

James Chih-Hsin Yang, MD, discusses the investigation of pembrolizumab plus pemetrexed and platinum-based chemotherapy in patients with TKI-resistant, EGFR-mutant, metastatic nonsquamous non–small cell lung cancer.

Dr Pellini on the Use of ctDNA Monitoring After Chemoimmunotherapy Induction in NSCLC

June 29th 2023

Bruna Pellini, MD, discusses the use of circulating tumor DNA monitoring to inform maintenance outcomes in patients with advanced non–small cell lung cancer treated with induction therapy with atezolizumab, carboplatin, and nab-paclitaxel.

Perioperative Treatment in Early-Stage NSCLC: AEGEAN Study

June 29th 2023

David Harpole, MD, discusses study design, results and clinical implications of the AEGEAN study of perioperative immunotherapy (neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in the treatment of early-stage NSCLC

Neoadjuvant Therapy in Early-Stage NSCLC: CheckMate-816 Study

June 29th 2023

Overview and clinical implications of the CheckMate-816 study of neoadjuvant nivolumab plus platinum chemotherapy versus chemotherapy alone in early-stage NSCLC.

Neoadjuvant Nivolumab/Chemo Wins EU Approval for Resectable PD-L1+ NSCLC

June 29th 2023

The European Commission has approved nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of patients with resectable non–small cell lung cancer at high risk of recurrence with tumor cell PD-L1 expression of at least 1%.

Dr Lam on the Tumor Microenvironment in ALK Fusion+ Lung Cancer

June 29th 2023

Vincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.

FDA Grants Fast Track Status to Quaratusugene Ozeplasmid Plus Atezolizumab in ES-SCLC

June 29th 2023

The FDA has granted fast track designation to the combination of quaratusugene ozeplasmid and atezolizumab as maintenance therapy in patients with extensive-stage small cell lung cancer whose disease did not progress after receiving initial standard treatment with atezolizumab and chemotherapy.

Repotrectinib NDA Under NMPA Review for Locally Advanced or Metastatic ROS1+ NSCLC

June 28th 2023

The National Medical Products Administration in China has accepted for review a new drug application seeking the approval of repotrectinib for use in adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.

Galinpepimut-S Plus Nivolumab Provides Survival Benefits With Acceptable Safety in Mesothelioma

June 28th 2023

The combination of galinpepimut-S and nivolumab provided positive survival outcomes with an acceptable safety profile in patients with malignant pleural mesothelioma who were refractory to or relapsed after at least 1 line of standard treatment.

Practical Considerations Regarding the Incorporation of Supportive Care Into Practice

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, consider the broader impact of supportive care on cost burden and quality of life and share scenarios in which supportive care is most appropriate.

Quality of Life and Patient-Reported Outcome Measures in SCLC Treatment

June 28th 2023

Jorge Nieva, MD, and Ashish Saxena, MD, PhD, share insights about the value of patient-reported outcomes studies and the extent to which they can shape treatment decisions.

Dr Murray on the Investigation of Prognostic Markers in Cemiplimab-treated NSCLC

June 27th 2023

Joseph Christopher Murray, MD, PhD, discusses the investigation of peripheral myeloid cells as prognostic markers in patients with non–small cell lung cancer treated with cemiplimab.

Examining LIFU–Aided Liquid Biopsy in Glioblastoma: Raising the Bar With the LIMITLESS Trial

June 27th 2023

In this fourth episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, discuss the key objectives of the phase 3 LIMITLESS study (NCT05317858) examining low-intensity focused ultrasound with immunotherapy and chemotherapy in patients with lung cancer and brain metastases.

Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLC

June 26th 2023

Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.

Camidge and Cetnar Revisit ASCO 2023 Data in Lung Cancer

June 26th 2023

In this episode of ‘How This is Building Me,’ Dr Camidge is rejoined by Dr Cetnar to discuss the good, the bad, and the ugly of the lung cancer data that were presented at the 2023 ASCO Annual Meeting.

Impact of Disease Staging on Prognosis and Treatment in SCLC

June 26th 2023

Panel experts review disease staging for limited and extensive stage small-cell lung cancer and discuss the impact of staging on treatment selection.

Importance of Early Referral and Diagnosis in Small-Cell Lung Cancer

June 26th 2023

Expert oncologists provide an overview of the landscape surrounding small-cell lung cancer and highlight the importance of early referral and diagnosis for overall patient outcomes.

Dr Wermke on the Investigation of BI 764532 in DLL3+ SCLC and NEC

June 23rd 2023

Martin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Selecting Optimal Treatment in Early-Stage NSCLC

June 23rd 2023

Ben Levy, MD offers insight into how he approaches the selection of the optimal treatment strategy in early-stage non-small cell lung cancer.

Overview of Early-Stage NSCLC and Molecular Testing

June 23rd 2023

A panel of experts who treat patients with non-small cell lung cancer provides an overview of staging, molecular testing and treatment options in stage I-IIIB non-small cell lung cancer.